Abstract:  Objective To examine whether infusion of antigen-activated memory T cells transfected with TCR genes alters the clinical efficacy and toxicity of pemetrexed-cisplatin combination chemotherapy to treatin the treatment of advanced non-small cell lung cancer resistant to EGFR-TKIs. Methods A total of 41 patients with non-small cell lung cancer were randomized into a group （n=20） that received standard chemotherapy involving a 3-week regime of pemetrexed（500 mg/m²） and cisplatin （75 mg/m²），or into a group（n=21） that received the same chemotherapy after harvesting， culturing and intravenously infusing DC-activated T cells.Curative effects，immune function， quality of life and adverse reactions were compared between the two treatments. Results Combining infu-sion of DC-activated T cells with chemotherapy significantly increased serum populations of CD3⁺，CD4⁺，CD8⁺，CD95⁺，and CD122⁺ cells，as well as the CD4⁺/CD8+⁺ratio.Combination therapy and standard chemotherapy alone gave similar overall response rates of 33.33% and 30.00% （P>0.05），respectively，but combination therapy led to a significantly higher disease control rate（76.19% vs 60.00%， P<0.05），longer median progression-free survival （7.1 vs 3.7 months， P<0.05），and a higher rate of improvement in KPS （karnofsky performance status）improvement rate（85.71% vs 45.00%， P<0.05）.At the same time，combination therapy was associated with much lower rates of neutropenia （46.6% vs 75.0%），nausea （52.4% vs 90.0%） and fatigue （23.8% vs 65.0%，P<0.05）. Conclusion Combining infusion of antigen-activated memory T cells with pemetrexed and cisplatin chemotherapy improves therapeutic response and immune function while also reducing side effects when treating patients with advanced non-small cell lung carcinoma resistant to EGFR-TKIs.This promising therapeutic approach should be explored further.

Key words: Lung neoplasm, EGFR-TKI, Pemetrexed, Cisplatin, Dendritic cell, TCR gene, Cytokine-induced killer cell